ATNAHS PHARMA US FDA Approval NDA 020067

NDA 020067

ATNAHS PHARMA US

FDA Drug Application

Application #020067

Documents

Letter2004-11-16
Letter2003-06-08
Letter2006-03-23
Letter2006-01-30
Letter2007-04-25
Letter2007-09-25
Letter2013-03-26
Letter2016-05-11
Label2004-11-16
Label2006-01-25
Label2007-09-26
Label2008-07-29
Label2013-03-26
Letter2004-11-16
Letter2008-07-30
Label2004-11-16
Label2006-03-14
Label2016-05-11
Label2017-03-13
Letter2017-03-14
Letter2019-07-23
Medication Guide2019-07-23
Label2019-07-23
Letter2021-04-29
Label2021-04-30
Medication Guide2021-04-30

Application Sponsors

NDA 020067ATNAHS PHARMA US

Marketing Status

Prescription002
Prescription003

Application Products

002TABLET, DELAYED RELEASE;ORAL375MG1EC-NAPROSYNNAPROXEN
003TABLET, DELAYED RELEASE;ORAL500MG1EC-NAPROSYNNAPROXEN

FDA Submissions

TYPE 3; Type 3 - New Dosage FormORIG1AP1994-10-14STANDARD
MANUF (CMC); Manufacturing (CMC)SUPPL2AP1996-06-28STANDARD
MANUF (CMC); Manufacturing (CMC)SUPPL3AP1997-07-09STANDARD
LABELING; LabelingSUPPL4AP2004-11-10STANDARD
LABELING; LabelingSUPPL5AP2003-05-19STANDARD
LABELING; LabelingSUPPL6AP2004-11-10STANDARD
MANUF (CMC); Manufacturing (CMC)SUPPL8AP2001-11-09STANDARD
MANUF (CMC); Manufacturing (CMC)SUPPL9AP2002-02-22STANDARD
LABELING; LabelingSUPPL10AP2006-03-10STANDARD
LABELING; LabelingSUPPL11AP2006-01-24STANDARD
LABELING; LabelingSUPPL13AP2007-04-19STANDARD
LABELING; LabelingSUPPL14AP2007-09-20STANDARD
LABELING; LabelingSUPPL17AP2008-07-25STANDARD
LABELING; LabelingSUPPL18AP2013-03-22STANDARD
LABELING; LabelingSUPPL19AP2016-05-09STANDARD
LABELING; LabelingSUPPL20AP2017-03-10STANDARD
LABELING; LabelingSUPPL21AP2019-07-22STANDARD
LABELING; LabelingSUPPL24AP2021-04-28STANDARD

Submissions Property Types

SUPPL1Null0
SUPPL2Null0
SUPPL3Null0
SUPPL8Null0
SUPPL9Null0
SUPPL18Null15
SUPPL19Null6
SUPPL20Null6
SUPPL21Null6
SUPPL24Null15

TE Codes

002PrescriptionAB
003PrescriptionAB

CDER Filings

ATNAHS PHARMA US
cder:Array
(
    [0] => Array
        (
            [ApplNo] => 20067
            [companyName] => ATNAHS PHARMA US
            [docInserts] => ["Medication Guide","https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/017581s115,018164s065,020067s024lbl.pdf#page=23"]
            [products] => [{"drugName":"EC-NAPROSYN","activeIngredients":"NAPROXEN","strength":"375MG","dosageForm":"TABLET, DELAYED RELEASE;ORAL","marketingStatus":"Prescription","te":"","rld":"Yes","rs":"Yes"},{"drugName":"EC-NAPROSYN","activeIngredients":"NAPROXEN","strength":"500MG","dosageForm":"TABLET, DELAYED RELEASE;ORAL","marketingStatus":"Prescription","te":"","rld":"Yes","rs":"Yes"}]
            [labels] => [{"actionDate":"04\/28\/2021","submission":"SUPPL-24","supplementCategories":"Labeling-Package Insert","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2021\\\/017581s115,018164s065,020067s024lbl.pdf\"}]","notes":""},{"actionDate":"07\/22\/2019","submission":"SUPPL-21","supplementCategories":"Labeling-Package Insert","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2019\\\/017581s114,018164s064,020067s021lbl.pdf\"}]","notes":""},{"actionDate":"03\/10\/2017","submission":"SUPPL-20","supplementCategories":"Labeling-Package Insert","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2017\\\/017581s113,018164s063,020067s020lbl.pdf\"}]","notes":""},{"actionDate":"05\/09\/2016","submission":"SUPPL-19","supplementCategories":"Labeling-Medication Guide","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2016\\\/017581s112,018164s062,020067s019lbl.pdf\"}]","notes":""},{"actionDate":"05\/09\/2016","submission":"SUPPL-19","supplementCategories":"Labeling-Package Insert","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2016\\\/017581s112,018164s062,020067s019lbl.pdf\"}]","notes":""},{"actionDate":"03\/22\/2013","submission":"SUPPL-18","supplementCategories":"Labeling-Package Insert","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2013\\\/017581s111,018164s061,018965s020,020067s018lbl.pdf\"}]","notes":""},{"actionDate":"07\/25\/2008","submission":"SUPPL-17","supplementCategories":"Labeling","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2008\\\/017581s110,18164s60,18965s18,20067s17lbl.pdf\"}]","notes":""},{"actionDate":"09\/20\/2007","submission":"SUPPL-14","supplementCategories":"Labeling","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2007\\\/017581s108,18164s58,18965s16,20067s14lbl.pdf\"}]","notes":""},{"actionDate":"03\/10\/2006","submission":"SUPPL-10","supplementCategories":"Labeling","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"\"}]","notes":""},{"actionDate":"01\/24\/2006","submission":"SUPPL-11","supplementCategories":"Labeling","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2006\\\/017581s106,018164s056,018965s014,020067s011lbl.pdf\"}]","notes":""},{"actionDate":"11\/10\/2004","submission":"SUPPL-6","supplementCategories":"Labeling","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2004\\\/17581s99,100,18164s50,51,18965s9,10,20067s4,6lbl.pdf\"}]","notes":""},{"actionDate":"11\/10\/2004","submission":"SUPPL-4","supplementCategories":"Labeling","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2004\\\/17581s99,100,18164s50,51,18965s9,10,20067s4,6lbl.pdf\"}]","notes":""}]
            [originalApprovals] => [{"actionDate":"EC-NAPROSYN","submission":"NAPROXEN","actionType":"375MG","submissionClassification":"TABLET, DELAYED RELEASE;ORAL","reviewPriority":"Prescription","inserts":"[]","notes":">Yes"},{"actionDate":"EC-NAPROSYN","submission":"NAPROXEN","actionType":"500MG","submissionClassification":"TABLET, DELAYED RELEASE;ORAL","reviewPriority":"Prescription","inserts":"[]","notes":">Yes"}]
            [supplements] => 
            [actionDate] => 2021-04-28
        )

)

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.